BCR-ABL fusion protein (b3a2)
BCR-ABL fusion protein (b3a2) (926-934) is a synthetic peptide fragment representing a specific epitope within the breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion, characteristic of the Philadelphia chromosome-positive chronic myeloid leukemia (CML). This fusion protein results from the translocation t(9;22)(q34;q11), which joins the BCR gene on chromosome 22 with the ABL gene on chromosome 9, generating a constitutively active tyrosine kinase that drives leukemogenesis. The b3a2 variant, defined by the fusion of BCR exon 13 (b3) to ABL exon 2 (a2), is one of the most prevalent molecular forms observed in CML patients. The 926-934 region corresponds to a unique peptide sequence at the fusion junction, making it highly relevant for molecular and immunological research targeting the BCR-ABL oncogenic protein.
Immunological assay development: The b3a2 (926-934) peptide is widely utilized as an immunogen or antigenic standard for the development and validation of immunoassays, such as enzyme-linked immunosorbent assays (ELISA) and immunoblotting protocols. Its sequence, spanning the BCR-ABL fusion junction, enables the generation of highly specific antibodies that discriminate between the oncogenic fusion protein and native BCR or ABL proteins. These assays are critical for detecting minimal residual disease, monitoring molecular remission, and supporting translational research into CML pathogenesis.
T-cell epitope mapping: As a defined peptide epitope, the b3a2 (926-934) sequence serves as a valuable tool for studying antigen-specific T-cell responses in the context of hematological malignancies. Researchers employ this peptide in vitro to stimulate patient-derived T cells, enabling the characterization of cytotoxic T lymphocyte (CTL) recognition, identification of HLA-restricted immune responses, and evaluation of immunogenicity. These insights inform the design of peptide-based immunotherapies and personalized cancer vaccine strategies targeting the BCR-ABL fusion.
Peptide-based vaccine research: The unique junctional sequence of the b3a2 (926-934) peptide provides a model antigen for preclinical studies investigating peptide vaccine formulations against CML. Its application in murine models and ex vivo human cell cultures supports the assessment of immunogenic potential, adjuvant efficacy, and the induction of targeted anti-leukemic immunity. Such studies advance the understanding of tumor-specific antigen presentation and contribute to the rational design of next-generation cancer immunotherapies.
Molecular diagnostics: The b3a2 (926-934) peptide is instrumental in the development of molecular diagnostic platforms aimed at identifying BCR-ABL-positive leukemias. By serving as a reference standard or positive control in mass spectrometry-based proteomic analyses, it facilitates the sensitive and specific detection of fusion protein expression in patient samples. This capability aids in disease classification, risk stratification, and the evaluation of therapeutic response at the molecular level.
Protein interaction studies: The defined structure of the b3a2 (926-934) peptide allows for detailed investigation of protein-protein and protein-ligand interactions involving the BCR-ABL fusion region. Researchers utilize this peptide in binding assays, structural biology experiments, and inhibitor screening platforms to elucidate the molecular mechanisms underlying kinase activation, substrate recognition, and the disruption of normal cellular signaling. These studies provide foundational knowledge for the development of targeted inhibitors and the advancement of precision oncology research.
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
2. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More